Last updated on July 2019

Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Hemophilia A and B
  • Age: Between 18 - 100 Years
  • Gender: Male

Inclusion Criteria:

  • Male severe hemophilic patients with undetectable FVIII activity <1% or FIX activity <2%, with or without inhibitors (any titer) are eligible.
  • Subjects with a past history of inhibitors (any inhibitor titer) are eligible.
  • Age 18 years.
  • Documentation of 4 bleeding episodes (any type or location of bleeds, treated or not) within the 6 months prior to screening.
  • For subjects on prophylaxis: Willingness to interrupt ongoing prophylaxis.
  • For subjects on immune tolerance induction (ITI): Willingness to interrupt ongoing ITI.

Exclusion Criteria:

  • History of any other coagulation disorder (particularly disseminated intravascular coagulopathy or combined FVIII/FV deficiency) or platelet disorder.
  • History of diseases related to venous thromboembolic events (e.g., pulmonary embolism, deep vein thrombosis, thrombophlebitis) or thrombotic microangiopathy.
  • Risk factors for venous or arterial diseases (e.g., uncontrolled hypertension, uncontrolled diabetes).
  • History of cardiac, coronary and/or arterial peripheral atherosclerotic disease
  • Platelet count <100,000/L.
  • Human immunodeficiency virus (HIV) infection with a cluster of differentiation 4 (CD4+) lymphocyte count of <200/mm3

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.